Proposed Data Collection Submitted for Public Comment and Recommendations, 59916-59917 [2024-16233]
Download as PDF
<![CDATA[
59916
Federal Register / Vol. 89, No. 142 / Wednesday, July 24, 2024 / Notices
interpreted by 46 CFR 545.5.
Complainant alleges this violation arose
from the assessment of detention
charges during periods when empty
containers could not be returned due to
reasons such as dual transaction
requirements and appointment
unavailability.
An answer to the complaint must be
filed with the Commission within 25
days after the date of service.
The full text of the complaint can be
found in the Commission’s electronic
Reading Room at https://www2.fmc.gov/
readingroom/proceeding/24-24/. This
proceeding has been assigned to the
Office of Administrative Law Judges.
The initial decision of the presiding
judge shall be issued by July 21, 2025,
and the final decision of the
Commission shall be issued by February
4, 2026.
David Eng,
Secretary.
[FR Doc. 2024–16260 Filed 7–23–24; 8:45 am]
BILLING CODE 6730–02–P
FEDERAL RESERVE SYSTEM
ddrumheller on DSK120RN23PROD with NOTICES1
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
applications are set forth in paragraph 7
of the Act (12 U.S.C. 1817(j)(7)).
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in paragraph 7 of
the Act.
Comments received are subject to
public disclosure. In general, comments
received will be made available without
change and will not be modified to
remove personal or business
information including confidential,
contact, or other identifying
information. Comments should not
VerDate Sep<11>2014
17:57 Jul 23, 2024
Jkt 262001
include any information such as
confidential information that would not
be appropriate for public disclosure.
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than August 8, 2024.
A. Federal Reserve Bank of Atlanta
(Erien O. Terry, Assistant Vice
President) 1000 Peachtree Street NE,
Atlanta, Georgia 30309. Comments can
also be sent electronically to
Applications.Comments@atl.frb.org:
1. John Adam Robertson; Aaron
Andrew Robertson; the Edwin G.
Robertson Children’s Irrevocable Trust,
John Adam Robertson, Trustee; and the
Craig E. Robertson Children’s
Irrevocable Trust, Aaron Andrew
Robertson, Trustee, all of Speedwell,
Tennessee; Emily Alayne King, Powell,
Tennessee; Erica Leigh Corum,
Harrogate, Tennessee; Matthew Craig
Robertson, Tazewell, Tennessee; and
Dakota John Robertson Bristol,
Tennessee; as a group acting in concert,
to retain voting shares of Robertson
Holding Company, L.P., Harrogate,
Tennessee. Robertson Holding
Company, L.P., controls Commercial
Bancgroup, Inc., which controls
Commercial Bank, both of Harrogate,
Tennessee.
In addition, Aaron Andrew Robertson;
Cynthia Diane Robertson; James Oscar
Robertson; John Adam Robertson, all of
Speedwell, Tennessee; Sherri Jo
Robertson and Noah Bradley Robertson,
both of Harrogate, Tennessee; Dakota
John Robertson, Bristol, Tennessee;
Judith Yvonne Robertson, Cumberland
Gap, Tennessee; Matthew Craig
Robertson and Matthew Craig Robertson
II, both of Tazewell, Tennessee; Olivia
Grace Robertson, Hanahan, South
Carolina; Emily Alayne King; Halle
McLayne King; John McKinley King; and
Riley Parker King, all of Powell,
Tennessee; as a group acting in concert
with Robertson Holding Company, L.P.,
to retain voting shares of Commercial
Bancgroup, Inc.
B. Federal Reserve Bank of Richmond
(Brent B. Hassell, Assistant Vice
President) P.O. Box 27622, Richmond,
Virginia 23261. Comments can also be
sent electronically to
Comments.applications@rich.frb.org:
1. Barry J. Renbaum, Carol E.
Renbaum, both individually and of
Reisterstown, Maryland, Bryan M.
Renbaum, individually, Frederick,
Maryland; to form the Renbaum Family
Control Group, a group acting in
concert, to acquire voting shares of
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
Farmers and Merchants Bancshares,
Inc., Hampstead, Maryland, and thereby
indirectly acquire voting shares of
Farmers and Merchants Bank, Upperco,
Maryland.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2024–16265 Filed 7–23–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–24–24HP; Docket No. CDC–2024–
0056]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Compliance
Attestation Statement for the
Framework for Nucleic Acid Synthesis
Screening. The project aims to assist
providers and manufacturers of
synthetic nucleic acids and benchtop
nucleic acid synthesis equipment
(providers) in making an attestation that
they have instituted a process to screen
nucleic acid sequences of concern and
verify customer legitimacy, in
accordance with the requirements
outlaid in the OSTP Framework for
Nucleic Acid Synthesis Screening.
DATES: CDC must receive written
comments on or before September 23,
2024.
SUMMARY:
You may submit comments,
identified by Docket No. CDC–2024–
0056 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
ADDRESSES:
E:\FR\FM\24JYN1.SGM
24JYN1
Federal Register / Vol. 89, No. 142 / Wednesday, July 24, 2024 / Notices
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
59917
for Nucleic Acid Synthesis Screening,
which was released by the Office of
Science and Technology Policy (OSTP)
in April of 2024. This framework was
directed by the Executive Order on the
Safe, Secure, and Trustworthy
Development of Artificial Intelligence,
and recommends that providers and
manufacturers of synthetic nucleic acids
screen their sequences and customers
before fulfilling orders to prevent
potential misuse.
The Attestation Form will collect
basic organizational information and an
attestation of compliance from providers
and manufacturers of synthetic nucleic
acids and benchtop nucleic acid
synthesis equipment. Data collected
includes organization name, location,
website, and type of organization. The
form also includes primary and
secondary contact information such as
name, location, phone number and
email address to ensure there is a point
of contact with the company in case of
questions regarding compliance and
record keeping. This data is needed to
ensure the self-attestation form can be
filed and logged correctly, and to ensure
the government can reach out to the
correct contact if clarification if
necessary.
CDC requests OMB approval for an
estimated 20 annual burden hours.
There is no cost to respondents other
than their time to participate.
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Compliance Attestation Statement for
the Framework for Nucleic Acid
Synthesis Screening—New—Office of
Science (OS), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
This data collection form was
developed pursuant to the Framework
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Form name
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total burden
(in hours)
Providers and manufacturers of synthetic nucleic acids and bench top
nucleic acid synthesis equipment.
Annual Provider and Manufacturer
Self-Attestation Statement.
60
1
20/60
20
Total ...........................................
...........................................................
........................
........................
........................
20
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2024–16233 Filed 7–23–24; 8:45 am]
[Document Identifier: CMS–10434 #66]
Centers for Medicare & Medicaid
Services
ddrumheller on DSK120RN23PROD with NOTICES1
BILLING CODE 4163–18–P
Medicaid and Children’s Health
Insurance Program (CHIP) Generic
Information Collection Activities:
Proposed Collection; Comment
Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
AGENCY:
VerDate Sep<11>2014
17:57 Jul 23, 2024
Jkt 262001
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
ACTION:
Notice.
On May 28, 2010, the Office
of Management and Budget (OMB)
issued Paperwork Reduction Act (PRA)
guidance related to the ‘‘generic’’
clearance process. Generally, this is an
expedited process by which agencies
may obtain OMB’s approval of
collection of information requests that
are ‘‘usually voluntary, low-burden, and
uncontroversial collections,’’ do not
raise any substantive or policy issues,
and do not require policy or
methodological review. The process
requires the submission of an
SUMMARY:
E:\FR\FM\24JYN1.SGM
24JYN1
]]>Agencies
[Federal Register Volume 89, Number 142 (Wednesday, July 24, 2024)]
[Notices]
[Pages 59916-59917]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-16233]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-24-24HP; Docket No. CDC-2024-0056]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies the opportunity to comment on a proposed information
collection, as required by the Paperwork Reduction Act of 1995. This
notice invites comment on a proposed information collection project
titled Compliance Attestation Statement for the Framework for Nucleic
Acid Synthesis Screening. The project aims to assist providers and
manufacturers of synthetic nucleic acids and benchtop nucleic acid
synthesis equipment (providers) in making an attestation that they have
instituted a process to screen nucleic acid sequences of concern and
verify customer legitimacy, in accordance with the requirements outlaid
in the OSTP Framework for Nucleic Acid Synthesis Screening.
DATES: CDC must receive written comments on or before September 23,
2024.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2024-
0056 by either of the following methods:
Federal eRulemaking Portal: www.regulations.gov. Follow
the instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600
[[Page 59917]]
Clifton Road NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to www.regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (www.regulations.gov) or by U.S. mail to the address listed
above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7570;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses; and
5. Assess information collection costs.
Proposed Project
Compliance Attestation Statement for the Framework for Nucleic Acid
Synthesis Screening--New--Office of Science (OS), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
This data collection form was developed pursuant to the Framework
for Nucleic Acid Synthesis Screening, which was released by the Office
of Science and Technology Policy (OSTP) in April of 2024. This
framework was directed by the Executive Order on the Safe, Secure, and
Trustworthy Development of Artificial Intelligence, and recommends that
providers and manufacturers of synthetic nucleic acids screen their
sequences and customers before fulfilling orders to prevent potential
misuse.
The Attestation Form will collect basic organizational information
and an attestation of compliance from providers and manufacturers of
synthetic nucleic acids and benchtop nucleic acid synthesis equipment.
Data collected includes organization name, location, website, and type
of organization. The form also includes primary and secondary contact
information such as name, location, phone number and email address to
ensure there is a point of contact with the company in case of
questions regarding compliance and record keeping. This data is needed
to ensure the self-attestation form can be filed and logged correctly,
and to ensure the government can reach out to the correct contact if
clarification if necessary.
CDC requests OMB approval for an estimated 20 annual burden hours.
There is no cost to respondents other than their time to participate.
Estimated Annualized Burden Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
--------------------------------------------------------------------------------------------------------------------------------------------------------
Providers and manufacturers of synthetic nucleic Annual Provider and Manufacturer 60 1 20/60 20
acids and bench top nucleic acid synthesis Self-Attestation Statement.
equipment.
-------------------------------------------------------------------
Total....................................... .................................. ............... ............... ............... 20
--------------------------------------------------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-16233 Filed 7-23-24; 8:45 am]
BILLING CODE 4163-18-P
